Table 2.
Clinical and pathologic characteristics of the study population as a function of BRMS1 expression
| BRMS1+ (n= 179) | BRMS1− (n= 59) | P | |
|---|---|---|---|
| Age (y) | |||
| <50 | 35 of 167 (21%) | 20 of 55 (36%) | |
| >50 | 132 of 167 (79%) | 35 of 55 (64%) | 0.02 |
| Tumor size | |||
| T1 | 90 of 160 (56%) | 33 of 56 (59%) | |
| T2 | 52 of 160 (32.5%) | 16 of 56 (28.5%) | |
| T3 | 12 of 160 (7.5%) | 2 of 56 (3.5%) | |
| T4 | 6 of 160 (4%) | 5 of 56 (9%) | 0.34 |
| Bloom-Richardson grade | |||
| 1 | 27 of 144 (19%) | 4 of 51 (8%) | |
| 2 | 69 of 144 (48%) | 31 of 51 (61%) | |
| 3 | 48 of 144 (33%) | 16 of 51 (31%) | 0.13 |
| Lymph node status | |||
| N0 | 94 of 151 (62%) | 27 of 52 (52%) | |
| N1 | 37 of 151 (25%) | 16 of 52 (31%) | |
| N2 | 14 of 151 (9%) | 5 of 52 (9%) | |
| N3 | 6 of 151 (4%) | 4 of 52 (8%) | 0.50 |
| ER | |||
| Negative | 33 of 178 (19%) | 17 of 59 (29%) | |
| Positive | 145 of 178 (81%) | 42 of 59 (71%) | 0.09 |
| PR | |||
| Negative | 61 of 178 (34%) | 32 of 59 (54%) | |
| Positive | 117 of 178 (66%) | 27 of 59 (46%) | 0.006 |
| HER2 | |||
| Negative | 161 of 179 (90%) | 47 of 59 (80%) | |
| Positive | 18 of 179 (10%) | 12 of 59 (20%) | 0.039 |